La Jolla, CA (PRWEB) July 23, 2014
StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study for Parkinson’s disease. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with degenerative diseases.
This clinical study makes stem cell therapy accessible to the millions of individuals currently living with Parkinson’s disease. The protocol used in these stem cell treatments is unique to StemGenex, having the possibility of being more effective than other stem cell treatments currently available. StemGenex has developed a multiple administration protocol for patients suffering from Parkinson’s disease which includes targeted methods of stem cell delivery. Among these methods is a novel approach for delivering stem cells past the blood brain barrier – an issue most stem cell treatments have been challenged by.
Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, “As is the case with most neurodegenerative conditions, there are few available drugs to treat Parkinson’s disease. The handful of drugs that are available can only ameliorate symptoms and unfortunately, prolonged usage can create terrible side-effects. Further, these drugs do not halt disease progression or aid in the repair of established damage. Our goal is to provide regenerative medicine applications that address these critical issues. The study we are conducting is designed to provide us with a large amount of rigorously collected data so that we can better understand the clinical benefit of Parkinson’s patients treated with stem cells.”
This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, “It is important patients have access to top-tier stem cell therapy. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.”
Rita Alexander, founder and president of StemGenex stated, “Parkinson's disease affects a very small part of the brain but anyone suffering with this disease understands the negative impact on his or her life is very big, actually, enormous. Over the last several years we have observed significant improvement in the symptoms of Parkinson’s patients through stem cell treatment. We are determined to be part of the solution and are eager to document and publish our findings in the next few years.”
Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Parkinson’s disease and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Alzheimer’s disease, stroke recovery and others.
To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com.